Table 3 Baseline characteristics of ICIs-treated patients with or without AKI events reported from FAERS database
Characteristics | All cases (N = 135,531) | AKI (N = 2948) | Non-AKI (N = 132,583) |
|---|---|---|---|
Reporter | |||
 Total data | 135,186 | 2945 | 132,241 |
 Healthcare professional | 112,981(83.6%) | 2841(96.5%) | 110,140(83.3%) |
 Non-healthcare professional | 22,205(16.4%) | 104(3.5%) | 22,101(16.7%) |
Sex | |||
 Total data | 119,777 | 2810 | 116,967 |
 Male | 74,398(62.1%) | 1882(67.0%) | 72,516(62.0%) |
 Female | 45,379(37.9%) | 928(33.0%) | 44,451(38.0%) |
Age | |||
 Total data | 95,464 | 2679 | 92,785 |
  < 65YR | 44,321(46.4%) | 1074(40.1%) | 43,247(46.6%) |
  ≥ 65YR | 51,143(53.6%) | 1605(59.9%) | 49,538(53.4%) |
Reported countries | |||
 Total data | 135,118 | 2938 | 132,180 |
 United States, US | 56,363(41.7%) | 1112(37.8%) | 55,251(41.8%) |
 Japan, JP | 20,905(15.5%) | 269(9.2%) | 20,636(15.6%) |
 France, FR | 11,520(8.5%) | 468(15.9%) | 11,052(8.4%) |
 Germany, DE | 7422(5.5%) | 278(9.5%) | 7144(5.4%) |
 Canada, CA | 4755(3.5%) | 58(2.0%) | 4697(3.6%) |
 United Kingdom, GB | 3600(2.7%) | 157(5.3%) | 3443(2.6%) |
 Australia, AU | 3122(2.3%) | 55(1.9%) | 3067(2.3%) |
 Italy, IT | 3012(2.2%) | 63(2.1%) | 2949(2.2%) |
 China, CN | 2613(1.9%) | 11(0.4%) | 2602(2.0%) |
 Spain, ES | 2504(1.9%) | 76(2.6%) | 2428(1.8%) |
 Other countries | 19,302(14.3%) | 391(13.3%) | 18,911(14.3%) |
Indications | |||
 Total data | 135,531 | 2948 | 132,583 |
 Lung cancer | 38,720(28.6%) | 755(25.6%) | 37,965(28.6%) |
 Melanoma | 29,989(22.1%) | 787(26.7%) | 29,202(22.0%) |
 Renal cancer | 10,888(8.0%) | 330(11.2%) | 10,558(8.0%) |
 Hepatocellular carcinoma | 2768(2.0%) | 69(2.3%) | 2699(2.0%) |
 Head and neck cancer | 2651(2.0%) | 44(1.5%) | 2607(2.0%) |
 Gastric cancer | 2436(1.8%) | 41(1.4%) | 2395(1.8%) |
 Bladder cancer | 2065(1.5%) | 97(3.3%) | 1968(1.5%) |
 Colorectal cancer | 2034(1.5%) | 54(1.8%) | 1980(1.5%) |
 Other cancers | 43,980(32.5%) | 771(26.2%) | 43,209(32.6%) |